# VNP40101M in Treating Patients With Advanced or Metastatic Cancer

> **NCT00049699** · PHASE1 · COMPLETED · sponsor: **Vion Pharmaceuticals**

## Conditions studied

- Lymphoma
- Small Intestine Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** laromustine

## Key facts

- **NCT ID:** NCT00049699
- **Lead sponsor:** Vion Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2008-01
- **Target enrollment:** — (—)
- **Last updated:** 2013-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049699, "VNP40101M in Treating Patients With Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00049699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*